Literature DB >> 11843299

Plasma thrombopoietin in patients with cavernous transformation of the portal vein.

Hakan Göker1, Türker Egesel, Sema Karakuş, Ibrahim C Haznedaroglu, Sule Apraş, Yahya Büyükaşic, Nilgün Sayinalp, Osman I Ozcebe, Semra Dundar, Serafettin Kirazli, Yusuf Bayraktar.   

Abstract

Thrombopoietin (TPO), the primary regulator of thrombopoiesis, is produced mainly in the liver. Previous studies investigating blood TPO in chronic liver diseases revealed conflicting results. It has been suggested that hepatic TPO production is regulated by the portal blood supply to the liver. However, the role of TPO in the pathobiological basis of idiopathic portal vein thrombosis (PVT) and cavernous transformation of the portal vein (CTPV) has not been elucidated. The objective of this study is to assess plasma TPO concentrations in patients with CTPV. Eleven patients (4 men and 7 women, aged 38+/-12 years) with CTPV were studied. Sixteen healthy adults served as the control group (8 men and 8 women, aged 34+/-12 years). Median plasma TPO concentration was 326 pg/mL (range, 15-1402 pg/mL) in the patients with CTPV and 62.65 pg/mL (range, 38.5-102 pg/mL) in the control group (P = .003). In this study, we found significantly higher TPO concentrations in the plasma of patients with CTPV. The higher concentrations could be a result of the altered portal hemodynamics due to thrombosis. Moreover, TPO release by activated platelets might lead to the subsequent propagation of thrombosis in PVT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11843299     DOI: 10.1007/bf02981986

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  24 in total

1.  Thrombocytopenia in liver transplant recipients: predictors, impact on fungal infections, and role of endogenous thrombopoietin.

Authors:  F Y Chang; N Singh; T Gayowski; M M Wagener; S M Mietzner; J E Stout; I R Marino
Journal:  Transplantation       Date:  2000-01-15       Impact factor: 4.939

2.  Effects of megakaryocyte growth and development factor (thrombopoietin) on liver endothelial cells in vitro.

Authors:  J E Cardier
Journal:  Microvasc Res       Date:  1999-09       Impact factor: 3.514

Review 3.  Thrombopoietin: its role from early hematopoiesis to platelet production.

Authors:  F Wendling
Journal:  Haematologica       Date:  1999-02       Impact factor: 9.941

4.  Plasma thrombopoietin levels in liver cirrhosis and kidney failure.

Authors:  D Stockelberg; P Andersson; E Björnsson; S Björk; H Wadenvik
Journal:  J Intern Med       Date:  1999-11       Impact factor: 8.989

5.  Hepatic thrombopoietin mRNA levels in acute and chronic liver failure of childhood.

Authors:  E M Wolber; R Ganschow; M Burdelski; W Jelkmann
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

6.  Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis.

Authors:  T Kawasaki; A Takeshita; K Souda; Y Kobayashi; M Kikuyama; F Suzuki; F Kageyama; Y Sasada; E Shimizu; G Murohisa; S Koide; T Yoshimi; H Nakamura; R Ohno
Journal:  Am J Gastroenterol       Date:  1999-07       Impact factor: 10.864

7.  Plasma thrombopoietin level after liver transplantation: relationship to cold ischemia time and coagulation parameters.

Authors:  P M Dobado-Berrios; C López-Pedrera; F Soriano; M de la Mata; R Guerrero; A Torres; F Velasco
Journal:  Intensive Care Med       Date:  2000-06       Impact factor: 17.440

8.  Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation.

Authors:  T G Martin; K A Somberg; Y G Meng; R L Cohen; C A Heid; F J de Sauvage; M A Shuman
Journal:  Ann Intern Med       Date:  1997-08-15       Impact factor: 25.391

9.  Transient thrombopoietin peak after liver transplantation for end-stage liver disease.

Authors:  M Faeh; S P Hauser; U E Nydegger
Journal:  Br J Haematol       Date:  2001-02       Impact factor: 6.998

10.  Direct evidence for an increase in thrombopoiesis after liver transplantation.

Authors:  G Stiegler; P Stohlawetz; M Peck-Radosavljevic; B Jilma; J Pidlich; M Wichlas; P Höcker; S Panzer
Journal:  Eur J Clin Invest       Date:  1998-09       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.